We have described that MMP-9 C − 1562 T and (CA) n polymorphisms contribute to multiple sclerosis (MS). Here, we evaluate whether plasma MMP-9 levels are related to disease severity, drug therapy resistance and polymorphisms. For sub-study 1, 36 patients with MS and 35 controls were recruited. For sub-study 2, 88 individuals (53 patients and 35 controls) were included in a cross-sectional analysis. MS patients presented higher MMP-9 activity (1.4 ± 0.18 versus 0.93 ± 0.18 A.U. for control, P b 0.05). Drug-therapy resistant individuals exhibited increased MMP-9 activity (1.96 ± 0.25 versus 1.21 ± 0.09 A.U. for non-resistant patients). EDSS score was also related to MMP-9 levels. The CT + TT and HH genotypes had higher MMP-9 levels as compared to patients carrying the CC and LL. Drug therapy resistance, disease severity, MMP-9 plasma activity and polymorphisms are associated with MS.
Introduction
Multiple sclerosis (MS) is considered to be a chronic neurological cell mediated autoimmune disease. The relapsing-remitting phase of the disease is associated with bursts of white matter inflammation in the brain and spinal cord, which causes focal demyelination followed or not by incomplete remyelination and gliosis (scarring). Axonal and neuronal damage predominates during the chronic phase. Accumulation of myelin loss and axonal damage over time often culminates in disabling central nervous system (CNS) disease. The lesions are mainly triggered by autoreactive inflammatory cells migrating through the damaged blood-brain barrier (BBB) into the CNS (Hauser and Oksenberg, 2006; Hauser, 2008) .
Matrix metalloproteinases (MMPs), particularly MMP-9, seem to be essential for inflammatory cell migration to the CNS in MS (Gijbels et al., 1992 (Gijbels et al., , 1993 Lee et al., 1999) . MMP-9 levels have been found to be augmented in the serum and cerebrospinal fluid of MS patients (Gijbels et al., 1992; Liuzzi et al., 2002; Avolio et al., 2003; Boz et al., 2006; Fainardi et al., 2006) . Moreover, circulating MMP-9 levels have been considered to be a therapeutic response biomarker to IFN-beta (Comabella et al., 2009; Alexander et al., 2010) , a drug that is commonly employed in the treatment of MS. In addition, the transcriptional activity of the MMP-9 gene may be influenced by two polymorphisms in the promoter region, namely the microsatellite (CA) n 13-25 (rs3222264) and the single nucleotide C − 1562 T (rs3918242) polymorphisms (Shimajiri et al., 1999; Zhang et al., 1999) . Our group has demonstrated that association of variants of these two polymorphisms is related to MS (Fernandes et al., 2009) . Therefore, the aim of the current study was to compare the plasma MMP-9 levels of MS patients and healthy controls (sub-study 1), and to verify whether the MMP-9 levels are related to the clinical status or resistance to drug therapy. In addition, we have evaluated whether the (CA) n 13-25 and C designed as a case-control study, and a total of 71 subjects were enrolled for it. More specifically, the study group consisted of 36 patients (all Caucasian, 83% female, aged 38 ± 12 years) fulfilling the revised McDonald's criteria for MS (Polman et al., 2005) . All the patients were recruited from the Division of Neuroimmunology of the University Hospital of the Medical School of Ribeirão Preto and were examined by the same neurologists (DGB and AAB) at the MS center of the Division. The control group was matched to the MS group for age (39 ± 13 years), ethnicity (all Caucasian), and gender (86% female). It consisted of 35 healthy subjects recruited from the general community, with no family history of MS or any other autoimmune diseases. Fifty-three patients (Caucasian, 84% female, and 38.5 ± 12 years) were recruited for the sub-study 2. Besides the conventional neurological examination, the disability degree was evaluated by using the Clinical Expanded Disability Status Scale (EDSS) (Kurtzke, 1983) . Thirty six percent of the patients had EDSS between 0.0 and 2.0 (n = 19); 29% had EDSS in the range of 2.5-4.0 (n = 16); 27% had EDSS lying between 4.5 and 6.0 (n = 14), and 8% had EDSS ranging from 6.5 to 8.0 (n = 4). Response to treatment was assessed by a single neurologist in a blinded fashion on the basis of review of medical records and relapse diaries. Patients who had remained relapse-free for ≥24 months on their current drug therapy regimen were classified as responders (n = 37), irrespective of the dose. Those who had continued to experience relapses over the previous 24 follow-up months despite prior exposure to appropriate drug therapy regimens were considered to be non-responders (n = 16). The same control group (n = 35) was included in sub-study 2, to verify the effect of MMP-9 polymorphisms on MMP-9 activity.
Genotyping
Subjects were genotyped for C T polymorphism by polymerase chain reaction (PCR) amplification using the primers 5′-GCC TGG CAC ATA GTA GGC CC-3′ (sense) and 5′-CTT CCT AGC CAG CCG GCATC-3′ (antisense), following the previously described PCR conditions (Zhang et al., 1999) . The amplified products were digested with Sph I (New England Biolabs, Ipswich, MA, USA) overnight at 37°C, generating fragments of 247 and 188 bp in the case of a polymorphic variant (allele "T"), or an undigested 435 bp band in the case of a wild type allele (allele "C"). Fragments were separated by electrophoresis in 12% polyacrylamide gels and visualized by silver staining as described earlier (Demacq et al., 2006) . Some recognized DNA variants were genotyped in parallel as RFLP technique controls. To determine the genotypes for the (CA) n polymorphism, PCR was carried out using the primers 5′-GAC TTG GCA GTG GAG ACT GCG GGC A-3′ (sense) and 5′-GAC CCC ACC CCT CCT TGA CAG GCA A-3′ (antisense), as previously described (Maeda et al., 2001) . The PCRs were performed in a 25 μL mixture containing 500 ng DNA, 20 pmol of each primer, 0.2 mM of each dNTP, 1.5 mM MgCl 2 , 1.0 U Taq polymerase, and 2.5 μL 10× PCR buffer. After initial denaturation at 95°C for 3 min, the samples were subjected to 30 cycles of amplification, which consisted of denaturation for 1 min at 95°C, annealing for 1 min at 69°C, and extension for 1 min at 72°C, followed by a final extension for 10 min. The amplified products were separated in a 7% polyacrylamide-urea gel and visualized by silver staining (Demacq et al., 2008) . Differences in molecular weight (or number of bases) from 144 bp (13 repeats) to 168 bp (25 repeats) were determined by comparison with migration of a 10 bp DNA ladder (Invitrogen Corporation, Carlsbad, CA, USA) and with some samples from homozygotes that had been sequenced. DNA sequencing of control homozygote variants had been accomplished, in order to verify the precise CA repeat numbers. This procedure was standardized as described earlier (Nelissen et al., 2000; Demacq et al., 2008) . The samples were classified as lower (L) than 21 CA repeats or higher (H) than 21 CA repeats.
MMP-9 SDS-polyacrylamide gel electrophoresis gelatin zymography
Plasma MMP-9 gelatin zymography was conducted as previously described (Demacq et al., 2008) . Briefly, plasma samples were subjected to electrophoresis on 7% SDS-PAGE co-polymerized with gelatin (1%) as the substrate. After the electrophoresis was complete, the gel was incubated for 1 h at room temperature in a 2% Triton X-100 solution, followed by incubation at 37°C for 16 h in Tris-HCl buffer, pH 7.4, containing 10 mmol/L CaCl 2 . The gels were stained with 0.05% Coomassie Brilliant Blue G-250, followed by destaining with 30% methanol and 10% acetic acid. Gelatinolytic activities were detected as unstained bands against the background of Coomassie blue-stained gelatin. Enzyme activity was assayed by densitometry using a Kodak Electrophoresis Documentation and Analysis System (EDAS) 290 (Kodak, Rochester, NY). Only the pro-form (pro-) MMP-9 bands were analyzed, identified as bands at 92 kDa by the relation of log Mr to the relative mobility of Sigma SDS-PAGE LMW marker proteins.
Statistical analysis
Continuous variable was compared by the unpaired Student's ttest or ANOVA. Contingency table-based analysis was used for comparisons of nominal variables, including genotype frequencies. Data were reported as the mean ± S.D. The group comparisons were assessed by one-way analysis of variance, followed by Bonferroni's multiple comparison test selected pair comparisons. A P value b 0.05 was considered as the minimum level of statistical significance.
Results

Sub-study 1
Healthy volunteers and MS patients were matched for gender, age, and ethnicity, with no significant difference between groups. Plasma MMP-9 levels were compared between MS and healthy individuals groups. As expected, plasma MMP-9 levels were significantly higher in MS patients than those measured in healthy volunteers (1.4 ± 0.18 versus 0.93 ± 0.18 A.U., respectively P b 0.05, Fig. 1 ).
Sub-study 2
Interestingly, when MS participants were analyzed for drug resistance, patients with more than 2 relapses in a period of 2 years, classified as resistant to therapy, presented significantly higher plasma MMP-9 levels (61%) as compared to responsive patients (1.96 ±0.25 versus 1.21 ± 0.09 A.U., respectively P b 0.05, Fig. 2A ).
When MS patients were classified by clinical status, the results indicated a progressively increasing plasma MMP-9 activity in more severely affected groups, as represented by the EDSS score range ( Fig. 2B , P b 0.0001). For example, group S4 presented 2.6 times higher MMP-9 values as compared to S1 (2.62 ± 0.63 A.U. versus 1.02 ± 0.37 A.U.).
Our group has already described that MMP-9 genotypes and haplotypes are associated with MS and with the degree of disability caused by the disease (Fernandes et al., 2009 ). The genotype frequencies in the MS population evaluated here (n = 53) were 75% CC, 23% CT, and 2% TT for the C − 1562 T polymorphism, and 15% LL, 38% LH, and 47% HH for the (CA) n polymorphism, as shown in Fig. 2C and D. In the control group (n = 35), CC, CT, and TT genotype frequencies were 77%, 20%, and 3%, respectively. Regarding (CA) n polymorphism, 17%, 43%, and 40% of the subjects were LL, LH and HH, respectively. The distribution of genotypes for the two polymorphisms studied herein showed no deviation from the Hardy-Weinberg equilibrium in control and MS groups.
In the present study, it has been investigated whether MMP-9 C − 1562 T and (CA) n polymorphisms are related to MMP-9 activity in control and MS individuals. Since the TT genotype frequency is very low, both CT and TT carriers were grouped. There was a significant difference in the plasma MMP-9 levels of MS patients that presented C to T substitution (CT + TT carriers). Patients carrying CC genotype presented plasma MMP-9 levels of 1.21 ± 0.06 A.U. as compared to 2.13 ± 0.016 A.U. found in the CT + TT group (P b 0.0001, Fig. 2C ). In addition, an overall different distribution of plasma MMP-9 levels was observed among (CA) n genotypes (P b 0.04; Fig. 2B ). It was verified that MS patients with the HH genotype, who carry a higher number of CA repeats in the MMP-9 gene, tended to exhibit higher (about 55%) pro-MMP-9 activity as compared to genotypes with lower (CA) numbers (Fig. 2D) . However, control subjects displayed equal MMP-9 activity among genotypes for both polymorphisms. Healthy individuals carrying CT + TT genotypes presented plasma MMP-9 levels of 0.59 ± 0.38 A.U. as compared to 0.45 ± 0.38 A.U. found in the CC group (P > 0.05). Similarly, carriers of the HH genotype had plasma MMP-9 levels of 0.51 ± 0.39 A.U., whereas HL and LL genotypes presented 0.36 ± 0.27 and 0.54 ± 0.50 A.U. (P > 0.05), respectively.
Discussion
It has been described that MMP-9 is involved in MS pathogenesis (Gijbels et (Lee et al., 1999; Waubant et al., 1999) and cerebrospinal fluid (Leppert et al., 1998; Lichtinghagen et al., 1999) of MS patients. Although these previous studies have not measured MMP-9 in plasma, determination of plasma MMP-9 activity by zymography has been used as an excellent MMP-9 biomarker, once the plasma is free of platelet activation derivatives, which cause augmentation of MMP-9 activity Gerlach et al., 2005 Gerlach et al., , 2007 .
When MS patients were classified according to the degree of disability and plasma MMP-9 levels were measured, we found that severe disability status was related to higher MMP-9 levels. The time course of MMP-9 regulation in MS patients is unclear. MMP activity does not seem to be regulated between relapses and stable phases (Leppert et al., 1998) . However, our findings suggest that patients with more than 2 relapses during a two year drug therapy followup period (drug resistance) present higher MMP-9 levels as compared to patients that responded to therapy. Thus, active phases could be related to higher MMP-9 activity. Our analysis was related to episodes that occurred irrespective of the drug used during the treatment. These data are in consonance with other results describing that MS patients classified as responders to IFN-beta treatment (presenting no relapses over 2 years of treatment) have their MMP-9/ TIMP-1 balance restored (Boz et al., 2006; Comabella et al., 2009) .
The second part of this study aimed to correlate MMP-9 C − 1562 T and (CA) n polymorphisms with plasma MMP-9 levels. In vitro studies have shown that the C to T substitution at the −1562 position results in loss of a nuclear repressor protein binding, thus leading to increased MMP-9 expression (Zhang et al., 1999) . The microsatellite (CA) n near the −90 position of the MMP-9 gene, which corresponds to a sequence of variable numbers of cytosine-adenine repeats (13-27) and has a bimodal distribution of allele frequencies (peaks in CA ≤ 14 and CA ≥ 21-23) (Shimajiri et al., 1999) , also seems to be functionally relevant. This polymorphism displays alleles representing lower repeats (L), thereby eliciting a 50% reduction in the MMP-9 promoter activity as compared to higher repeat alleles (H), which enhance such activity. In accordance with these in vitro studies, we found that MS patients carrying the T allele (CT + TT genotypes) or the HH genotype present significantly higher plasma MMP-9 levels. These results agree with our previous report showing that genotypes for patients and controls are given. *P b 0.05 vs. healthy individuals by one-way analysis of variance, followed by Bonferroni's multiple comparison test selected pair comparisons.
with the T allele and the H allele are significantly more frequent in MS patients with higher degree of disability (Fernandes et al., 2009) . The data presented here indicate that these polymorphisms are functional in MS patient, as determined by plasma MMP-9 levels. The low number of patients analyzed in the present study has not allowed for the establishment of a correlation among drug resistance, degree of disability, and plasma MMP-9 levels. However, the MMP-9 genotype analysis could be a way of selecting a specific group of patients prone to be responders to pharmacological intervention with MMP-9 inhibitors as adjuvant of MS classical therapies. Our results are reinforced by the haplotype analysis of MS patients. We have earlier described that haplotypes of the MMP-9 C − 1562 T and (CA) n polymorphisms are associated with the degree of disability in a Brazilian population of MS patients (Fernandes et al., 2009) . The results of the latter study showed that the T-L haplotype is significantly more frequent in severely affected patients as compared to controls. These previous data have been recently corroborated by a study reporting that individuals carrying the same T-L haplotype are more susceptible to MS initiation in an Italian population (La Russa et al., 2010) , thus supporting the hypothesis that an important role is played by the MMP-9 gene in MS. Interestingly, the MS patients participating in our studies were tested predominantly for the DRB*1501 allele and also have a predominant Italian ancestry (Brum et al., 2007) , again reinforcing this hypothesis. Recently, a GWAS has reported strong evidence of association between the SNP (rs2425752) and multiple sclerosis patients (International Multiple Sclerosis Genetics Consortium et al., 2011) . This SNP is located in the CD40 gene that is very close to the MMP-9 gene (about 66,000 bp from C − 1562 T), suggesting that both variants may be related to MS. The small sample size of the current study hinders an analysis addressing this issue. In conclusion, our findings point to an important role played by MMP-9 polymorphisms in modulating circulating MMP-9 production in individuals affected by MS. Moreover, the MMP-9 genotypic approach to MS may be useful as a prognostic biomarker of drug resistance and may aid recommendation of new viable possibilities of therapeutic intervention.
